Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
J Clin Endocrinol Metab ; 92(8): 3285-91, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17535988

ABSTRACT

CONTEXT: Women with polycystic ovary syndrome (PCOS) have anovulation due to arrested follicular maturation. The substrate (2-hydroxyestrogen) and product (2-methoxyestrogen) of catechol-O-methyl transferase (COMT) have been shown to modulate proliferation and angiogenesis of granulosa cells. OBJECTIVE: The objective of the study was to evaluate COMT ovarian expression as well as the production of estrogen metabolites (2-hydroxyestrogen and 2-methoxyestrogen) in subjects with PCOS. DESIGN: Immunohistochemistry was used to assess COMT expression in ovarian tissues. Urinary levels of 10 different estrogens and estrogen metabolites were measured using enzyme-labeled immunoassays and/or liquid chromatography with tandem mass spectrometry. SETTING: The study was conducted at a tertiary university referral center. PATIENTS AND OTHER PARTICIPANTS: Ovarian tissues were obtained from six control subjects and six subjects with PCOS. Fasting first-void urinary samples were collected from 49 subjects with PCOS and 36 healthy control subjects. MAIN OUTCOME MEASURE(S): COMT protein expression in ovarian tissues was measured. Urinary levels of 2-hydroxyestrogen and 2-methoxyestrogen levels in PCOS patients were also measured. RESULTS: Whereas immunohistochemistry showed that COMT was expressed in ovaries from control and PCOS subjects, its expression was significantly higher in ovaries from subjects with PCOS, in both the follicular structures and ovarian stroma. The urinary 2-hydroxyestrogen level was significantly lower in subjects with PCOS, compared with normal controls (P = 0.009). Additionally, urinary 2-hydroxyestrogen levels negatively correlated with serum insulin levels in subjects with PCOS (r = -0.333, P =0 .031). CONCLUSIONS: Urinary 2-hydroxyestrogen is decreased in subjects with PCOS, which could be due in part to increased ovarian expression of COMT. Further studies are needed to ascertain the role of estrogen metabolism in PCOS before this information can be used in clinical settings.


Subject(s)
Estrogens, Catechol/urine , Polycystic Ovary Syndrome/urine , Adult , Body Mass Index , Catechol O-Methyltransferase/urine , Chromatography, High Pressure Liquid , Enzyme-Linked Immunosorbent Assay , Estrogens/urine , Female , Humans , Immunohistochemistry , Ovarian Follicle/enzymology , Ovarian Follicle/pathology , Ovary/enzymology , Spectrometry, Mass, Electrospray Ionization
2.
Cancer Sci ; 95(12): 955-61, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15596044

ABSTRACT

Using proteomic analysis, we previously identified calreticulin (CRT) as a potentially useful urinary marker for bladder cancer. Now, we have also identified gamma -synuclein (SNCG) and a soluble isoform of catechol-o-methyltransferase (s-COMT) as novel candidates for tumor markers in bladder cancer, by means of proteomic analysis. In the process of establishing a superior tumor marker system, we investigated the diagnostic value of a combination assay of these three proteins. Voided urine samples were obtained from 112 bladder cancer and 230 control patients. Urinary CRT, SNCG, and s-COMT were measured as a combined marker by quantitative western blot analysis. Relative concentration of each protein was calculated and the diagnostic value of a concomitant examination of these markers was evaluated by receiver operator characteristic analysis. With the best diagnostic cutoff, the overall sensitivity of the combined markers was 76.8% (95% confidence interval, 69-81%) with a specificity of 77.4% (72-80%), while those of a single use of CRT were 71.4% and 77.8%, respectively. When evaluated in relation to tumor characteristics, such as grade, stage, size, and outcome of urinary cytology, the diagnostic capacity of the combined markers was equal to or better than that of CRT in all categories. Concomitant use of CRT, SNCG, and s-COMT had higher sensitivity for detection of bladder cancer than did single use of CRT. Our study suggests that use of this panel of markers will improve the diagnosis of bladder cancer and may allow the development of a protein microarray assay or multi-channel enzyme-linked immunosorbent assay.


Subject(s)
Biomarkers, Tumor/urine , Calreticulin/urine , Catechol O-Methyltransferase/urine , Nerve Tissue Proteins/urine , Urinary Bladder Neoplasms/diagnosis , Aged , Aged, 80 and over , Blotting, Western , Breast Neoplasms/diagnosis , Breast Neoplasms/urine , Carcinoma, Renal Cell/diagnosis , Carcinoma, Renal Cell/urine , Case-Control Studies , Electrophoresis, Gel, Two-Dimensional , Female , Humans , Kidney Neoplasms/diagnosis , Kidney Neoplasms/urine , Male , Middle Aged , Neoplasm Staging , Prognosis , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/urine , Proteomics , Sensitivity and Specificity , Synucleins , Urinary Bladder/metabolism , Urinary Bladder Neoplasms/urine , gamma-Synuclein
3.
Br J Pharmacol ; 115(8): 1349-58, 1995 Aug.
Article in English | MEDLINE | ID: mdl-8564191

ABSTRACT

1. Administration of cyclosporine A (CsA; 50 mg kg-1 day-1, s.c.) for 14 days produced an increase in both systolic (SBP) and diastolic (DBP) blood pressure by 60 and 25 mmHg, respectively. The urinary excretion of dopamine, DOPAC and HVA was reduced from day 5-6 of CsA administration onwards (dopamine from 19 to 46%, DOPAC from 16 to 48%; HVA from 18 to 42%). In vehicle-treated rats, the urinary excretion of dopamine and DOPAC increased (from 7 to 60%) from day 5 onwards; by contrast, the urinary excretion of HVA was reduced (from 27 to 60%) during the second week. 2. No significant difference was observed between the Vmax and Km values of renal aromatic L-amino acid decarboxylase (AAAD) in rats treated with CsA for 7 and 14 days or with vehicle. 3. Km and Vmax of monoamine oxidase types A and B did not differ significantly between rats treated with CsA for 7 and 14 days or with vehicle. 4. Maximal catechol-O-methyltransferase activity (Vmax) in homogenates of renal tissues obtained from rats treated with CsA for 7 or 14 days was significantly higher than that in vehicle-treated rats; Km (22.3 +/- 1.5 microM) values for COMT did not differ between the three groups of rats. 5. The accumulation of newly-formed dopamine and DOPAC in cortical tissues of rats treated with CsA for 14 days was three to four times higher than in controls. The outflow of both dopamine and DOPAC declined progressively with time and reflected the amine and amine metabolite tissue contents. No significant difference was observed between the DOPAC/dopamine ratios in the perifusate of renal tissues obtained from CsA- and vehicle-treated rats. In addition, no significant differences were observed in k values or in the slope of decline of both DA and DOPAC between experiments performed with CsA and vehicle-treated animals. 6. The Vmax for the saturable component of L-3,4-dihydroxyphenylalanine (L-DOPA) uptake in renal tubules from rats treated with CsA was twice that of vehicle-treated animals. Km in CsA- and vehicle-treated rats did not differ. 7. The decrease in the urinary excretion of sodium and an increase in blood pressure during CsA treatment was accompanied by a reduction in daily urinary excretion of dopamine. This appears to result from a reduction in the amount of L-DOPA made available to the kidney and does not involve changes in tubular AAAD, the availability of dopamine to leave the renal cells and dopamine metabolism. The enhanced ability of the renal tissues of CsA-treated animals to synthesize dopamine, when exogenous L-DOPA is provided, results from an enhanced activity of the uptake process of L-DOPA in renal tubular cells.


Subject(s)
3,4-Dihydroxyphenylacetic Acid/metabolism , Blood Pressure/drug effects , Cyclosporine/pharmacology , Dopamine/metabolism , Homovanillic Acid/metabolism , 3,4-Dihydroxyphenylacetic Acid/urine , Animals , Aromatic-L-Amino-Acid Decarboxylases/metabolism , Aromatic-L-Amino-Acid Decarboxylases/urine , Catechol O-Methyltransferase/metabolism , Catechol O-Methyltransferase/urine , Creatinine/metabolism , Cyclosporine/administration & dosage , Dopamine/urine , Homovanillic Acid/urine , In Vitro Techniques , Injections, Subcutaneous , Kidney Cortex/drug effects , Kidney Cortex/metabolism , Kidney Tubules/drug effects , Kidney Tubules/metabolism , Levodopa/metabolism , Levodopa/pharmacology , Male , Monoamine Oxidase/metabolism , Monoamine Oxidase/urine , Potassium/metabolism , Rats , Rats, Wistar , Sodium/metabolism , Urea/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...